[
    "{\"step_by_step_thinking\": \"Amyloid plaques are a characteristic feature of Alzheimer's disease. Anti-amyloid antibodies are designed to target these plaques and potentially slow the progression of the disease. As of June 2021, the FDA has approved Aducanumab, an anti-amyloid antibody, for the treatment of Alzheimer's disease.\", \"answer_choice\": \"A\"}"
]